Maspin subcellular expression in wild-type and mutant TP53 gastric cancers

被引:13
|
作者
Gurzu, Simona [1 ,2 ]
Jung, Ioan [1 ]
Sugimura, Haruhiko [3 ]
Stefan-van Staden, Raluca Ioana [4 ]
Yamada, Hidetaka [3 ]
Natsume, Hiroko [3 ]
Iwashita, Yuji [3 ]
Szodorai, Rita [1 ]
Szederjesi, Janos [5 ]
机构
[1] George Emil Palade Univ Med Pharm Sci & Technol, Dept Pathol, Targu Mures 540139, Mures, Romania
[2] George Emil Palade Univ Med Pharm Sci & Technol, Res Ctr, Targu Mures 540139, Mures, Romania
[3] Hamamatsu Univ Sch Med, Dept Tumor Pathol, Hamamatsu, Shizuoka 4313192, Japan
[4] Natl Inst Res Electrochem & Condensed Matter, Bucharest 060021, Romania
[5] George Emil Palade Univ Med Pharm Sci & Technol, Intens Care Unit, Targu Mures 540139, Mures, Romania
关键词
p53; TP53; gene; Maspin; Gastric cancer; Carcinoma; COLORECTAL-CANCER; P53; SYSTEM;
D O I
10.4251/wjgo.v12.i7.741
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND Although the role of p53 in the evolution and prognosis of gastric cancer (GC) has been extensively examined, the exact mechanism of action is incompletely understood. In the last years, p53-target genes were supposed to be involved in the p53 pathway. One of them is the tumor-suppressor gene Maspin, which codifies the protein with the same name. Maspin activity depends on its subcellular localization. To our knowledge, the possible role ofTP53gene in Maspin subcellular localization, in GC cells, has not yet been studied in a large number of human samples. AIM To evaluate the possible role of wild-type and mutated p53 in Maspin subcellular localization. METHODS The present study included 266 consecutive patients with GC in whichTP53gene status, and mutations in exons 2 to 11, respectively, were analyzed and correlated with immunohistochemical expression of p53 and Maspin. RESULTS None of the 266 cases showed mutations in exon 9. The rate ofTP53mutations was 33.83%. The mutation rate was slightly higher in distally-located GCs, with a lower degree (<= 5 buds/ high power fields) of dyscohesivity (P< 0.01). The wild-type cases had a longer survival, compared with mutant GCs, especially in patients without lymph node metastases, despite the high depth of tumor infiltration (P= 0.01). The Dukes-MAC-like staging system was proved to have the most significant independent prognostic value (P< 0.01). The statistical correlations proved thatTP53gene mutations in exon 7 might induce knockdown of Maspin, but wild-type p53 can partially restore nuclear Maspin expression and decrease the metastatic potential of gastric adenocarcinoma cells. CONCLUSION Downregulated Maspin might be induced by mutations in exon 7 of theTP53gene but wild-type p53 can partially restore nuclear Maspin expression. These findings should be proved in experimental studies.
引用
收藏
页码:741 / 755
页数:15
相关论文
共 50 条
  • [21] Selinexor: Changing the paradigm in patients with TP53 wild-type endometrial cancer?
    Gouda, Mohamed A.
    Thein, Kyaw Z.
    MED, 2023, 4 (11): : 752 - 754
  • [22] Isolation of a novel TP53 target gene from a colon cancer cell line carrying a highly regulated wild-type TP53 expression system
    Takei, Y
    Ishikawa, S
    Tokino, T
    Muto, T
    Nakamura, Y
    GENES CHROMOSOMES & CANCER, 1998, 23 (01): : 1 - 9
  • [23] Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia
    Kogan, Aksinija A.
    Topper, Michael J.
    Dellomo, Anna J.
    Stojanovic, Lora
    McLaughlin, Lena J.
    Creed, T. Michael
    Eberly, Christian L.
    Kingsbury, Tami J.
    Baer, Maria R.
    Kessler, Michael D.
    Baylin, Stephen B.
    Rassool, Feyruz, V
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (27)
  • [24] Expression of wild-type and mutated TP53in breast carcinomas
    LO Baumbusch
    S Myhre
    A Langerød
    A Bergamaschi
    H Johnsen
    S Geisler
    PE Lønning
    A-L Børresen-Dale
    Breast Cancer Research, 7
  • [25] Transfection of wild-type TP53 induces differentiation in human gingival carcinoma cells
    Takahashi, R
    Inagaki, T
    Matsuwari, S
    Fujioka, M
    Maeda, S
    Ijuhin, N
    Haga, H
    Koh, T
    Shimada, K
    Saya, H
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (03) : 533 - 539
  • [26] The HDAC Inhibitor Panobinostat Promotes Expression of Δ133p53 Variants in TP53 Wild-type Bladder Cancer Cells
    Groselj, B.
    Brideau, C. M.
    Kerr, M.
    Kiltie, A. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S706 - S706
  • [27] TP53 Mutated del(5q) Myelodysplastic Syndromes (MDS) Patients Have Survivals Comparable to Those with TP53 Wild-Type
    Chan, Onyee
    Al Ali, Najla
    Sallman, David
    Padron, Eric
    Lancet, Jeffrey
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S324 - S324
  • [28] The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
    Leroy, Bernard
    Fournier, Jean Louis
    Ishioka, Chikashi
    Monti, Paola
    Inga, Alberto
    Fronza, Gilberto
    Soussi, Thierry
    NUCLEIC ACIDS RESEARCH, 2013, 41 (D1) : D962 - D969
  • [29] Nutlin-3α: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas
    Crane, Erin K.
    Kwan, Suet-Yan
    Izaguirre, Daisy I.
    Tsang, Yvonne T. M.
    Mullany, Lisa K.
    Zu, Zhifei
    Richards, JoAnne S.
    Gershenson, David M.
    Wong, Kwong-Kwok
    PLOS ONE, 2015, 10 (08):
  • [30] TP53 Wild-type Esophageal Squamous Cell Carcinoma Demonstrates Distinct Oncogenic Pathways
    Goksel, Behiye
    Zhao, Lei
    LABORATORY INVESTIGATION, 2023, 103 (03) : S554 - S555